CBIO vs OKUR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CBIO Captures Institutional Edge (2โ1 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crescent Biopharma, Inc. Common Stock (CBIO) driven by superior Momentum & Technical, Options & Structure while OKUR counters with relative strength in Growth & Margin. Fundamentally, CBIO trades at N/M Forward P/E with -1228.4% operating margin (+0.0% YoY revenue) versus OKUR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CBIO sits in BREAKDOWN (98th %ile IV; Dealer Gamma Walls on Pro) against OKUR sits in SURGE (100th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CBIO | OKUR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $539.5M | $113.7M | Larger Scale | CBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | -1228.4% | 0.0% | Higher Margin | OKUR |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -160.8% | -55.2% | Higher ROE | OKUR |
| 52-Week Range Position Momentum | 23% ($9โ$27) | 20% ($2โ$5) | Stronger Trend | CBIO |
| Beta / 30D Volatility Risk Regime | 1.18ฮฒ ยท 60% Vol | 0.96ฮฒ ยท 100% Vol | Lower Realized Risk | CBIO |
| Unified Institutional Score Composite Signal | 49.2 / 100 (HOLD) | 36.0 / 100 (SELL) | Higher Composite | CBIO |